PMID- 24333627
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20181203
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 175
DP  - 2014 Feb 10
TI  - Hybrid scaffold composed of hydrogel/3D-framework and its application as a 
      dopamine delivery system.
PG  - 10-6
LID - S0168-3659(13)00934-6 [pii]
LID - 10.1016/j.jconrel.2013.12.002 [doi]
AB  - Cell-based drug delivery systems (DDSs) have been increasingly exploited because 
      cells can be utilized as a continuous drug delivering system to produce 
      therapeutic molecules over a more extended period compared to the simple drug 
      carriers. Although hydrogels have many advantages for this application, their 
      mechanical properties are generally not desirable to structurally protect 
      implanted cells. Here, we present a three-dimensional (3D) hybrid scaffold with a 
      combination of a 3D framework and a hydrogel to enhance the mechanical properties 
      without chemically altering the transport properties of the hydrogel. Based on 
      the 3D Ormocomp scaffold (framework) fabricated by projection-based 
      microstereolithography with defined parameters, we developed a 3D hybrid scaffold 
      by injection of the mixture of cells and the alginate gel into the internal space 
      of the framework. This hybrid scaffold showed the improved mechanical strength 
      and the framework in the scaffold played the role of an adhesion site for the 
      encapsulated cells during the culture period. Additionally, we confirmed its 
      protection of exogenous human cells from acute immune rejection in a mouse model. 
      Eventually, we demonstrated the feasibility of applying this hybrid scaffold to 
      the treatment of Parkinson's disease as a cell-based DDS. Dopamine released from 
      the 3D hybrid scaffolds encapsulating dopamine-secreting cells for 8weeks 
      suggested its clinical applicability. Further study on its long-term efficacy is 
      necessary for the clinical applicability of this 3D hybrid scaffold for the 
      treatment of Parkinson's disease.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Kang, Kyung Shin
AU  - Kang KS
AD  - Department of Mechanical Engineering, Pohang University of Science and 
      Technology, Pohang 790-784, South Korea.
FAU - Lee, Soo-In
AU  - Lee SI
AD  - Agency for Defense Development, Daejeon 305-152, South Korea.
FAU - Hong, Jung Min
AU  - Hong JM
AD  - Department of Mechanical Engineering, Pohang University of Science and 
      Technology, Pohang 790-784, South Korea.
FAU - Lee, Jin Woo
AU  - Lee JW
AD  - Department of Mechanical Engineering, Pohang University of Science and 
      Technology, Pohang 790-784, South Korea.
FAU - Cho, Hwa Yeon
AU  - Cho HY
AD  - Department of Neurosurgery, Seoul National University Hospital, Seoul 110-774, 
      South Korea; Cancer Research Institute, Seoul National University College of 
      Medicine, Seoul 110-744, South Korea; Ischemic/Hypoxic Disease Institute, Seoul 
      National University College of Medicine, Seoul 110-774, South Korea.
FAU - Son, Jin H
AU  - Son JH
AD  - Department of Brain and Cognitive Science, Ewha Womans University, Seoul 120-750, 
      South Korea.
FAU - Paek, Sun Ha
AU  - Paek SH
AD  - Department of Neurosurgery, Seoul National University Hospital, Seoul 110-774, 
      South Korea; Cancer Research Institute, Seoul National University College of 
      Medicine, Seoul 110-744, South Korea; Ischemic/Hypoxic Disease Institute, Seoul 
      National University College of Medicine, Seoul 110-774, South Korea. Electronic 
      address: paeksh@snu.ac.kr.
FAU - Cho, Dong-Woo
AU  - Cho DW
AD  - Department of Mechanical Engineering, Pohang University of Science and 
      Technology, Pohang 790-784, South Korea. Electronic address: dwcho@postech.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131212
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Alginates)
RN  - 0 (Dopamine Agents)
RN  - 0 (Hexuronic Acids)
RN  - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate)
RN  - 8A5D83Q4RW (Glucuronic Acid)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Alginates/chemistry
MH  - Animals
MH  - Cells, Cultured
MH  - Dopamine/*administration & dosage
MH  - Dopamine Agents/*administration & dosage
MH  - Drug Delivery Systems/*methods
MH  - Female
MH  - Glucuronic Acid/chemistry
MH  - Hexuronic Acids/chemistry
MH  - Humans
MH  - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Parkinson Disease/drug therapy
MH  - Tissue Scaffolds/*chemistry
OTO - NOTNLM
OT  - Dopamine
OT  - Drug delivery system
OT  - Hydrogel
OT  - Parkinson's disease
OT  - Scaffold
EDAT- 2013/12/18 06:00
MHDA- 2014/09/17 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/06/15 00:00 [received]
PHST- 2013/10/08 00:00 [revised]
PHST- 2013/12/03 00:00 [accepted]
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - S0168-3659(13)00934-6 [pii]
AID - 10.1016/j.jconrel.2013.12.002 [doi]
PST - ppublish
SO  - J Control Release. 2014 Feb 10;175:10-6. doi: 10.1016/j.jconrel.2013.12.002. Epub 
      2013 Dec 12.